利拉鲁肽
透明质酸
医学
皮下注射
生物利用度
脂肪变性
药理学
药品
减肥
肥胖
内科学
内分泌学
2型糖尿病
生物医学工程
糖尿病
解剖
作者
Seorin Juhng,Jieun Song,Jeongyun You,Jihyun Park,Hyung Kook Yang,Mingyu Jang,Geonwoo Kang,Jiwoo Shin,Hye Su Min,Hyuk Wan Ko,Hyungil Jung
出处
期刊:Lab on a Chip
[The Royal Society of Chemistry]
日期:2023-01-01
卷期号:23 (10): 2378-2388
被引量:2
摘要
Obesity is a chronic metabolic disease that is prevalent worldwide, causing complications that affect the quality of life and longevity of humans. Currently, the low bioavailability upon subcutaneous injection of an appetite suppressant, liraglutide, and health problems in the locally injected region remain to be overcome. In this study, we developed a novel hyaluronic acid-based liraglutide-encapsulated triple-layer microneedle (TLM) as a painless and patient-friendly long-term drug delivery system. In contrast to previous anti-obesity microneedle approaches, this TLM is composed of three layers for complete skin insertion, protecting the encapsulated liraglutide from environmental stresses. Daily topical application of the liraglutide-loaded TLM significantly reduced body weight and improved body composition in a mouse model of high-fat diet-induced obesity. Additionally, it ameliorated diet-induced hepatic steatosis in obese mice. This novel TLM could promote a glucagon-like peptide-1 drug release system for long-term daily administration with relatively higher patient compliance compared to subcutaneous injection.
科研通智能强力驱动
Strongly Powered by AbleSci AI